Anti-Coagulants - Ghana | Statista Market Forecast

The Anti-Coagulants market in Ghana is expected to witness a significant growth in revenue, projected to reach US$6.23m in 2024.
This growth is anticipated to continue with an annual growth rate (CAGR 2024-2029) of 7.64%, leading to a market volume of US$9.00m by 2029.
When compared globally, it is noteworthy that United States will generate the highest revenue in this market, with an estimated revenue of US$16.74bn in 2024.
Ghana's market for anti-coagulants is experiencing a growing demand due to an aging population and an increase in chronic diseases.

Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson

Blood clotting inhibitors

Anti-fibrinolytics
Anti-hypertensives
Other hematology drugs
Other anti-thrombotic agents, such as platelet aggregation inhibitors
Thrombolytic drugs

The Anti-Coagulants market in Ghana has been experiencing steady growth in recent years.

Customer preferences: Patients in Ghana are increasingly seeking out preventative measures to avoid the development of blood clots, leading to an increase in demand for anti-coagulants. Additionally, the aging population in Ghana has contributed to the growth of the market as the elderly are more susceptible to conditions that require anti-coagulant medication.

Trends in the market: The Anti-Coagulants market in Ghana has seen an increase in the availability of direct oral anticoagulants (DOACs) which are more convenient for patients as they do not require regular blood tests. This has led to a shift away from traditional anti-coagulants such as warfarin. Additionally, there has been a rise in the use of anti-coagulants for the treatment of conditions such as stroke, deep vein thrombosis, and pulmonary embolism.

Local special circumstances: The healthcare system in Ghana is still developing and there are challenges in accessing healthcare services, particularly in rural areas. However, the government has made efforts to improve access to healthcare services and has implemented policies to increase the availability of medication, including anti-coagulants, in the country.

Underlying macroeconomic factors: Ghana has experienced economic growth in recent years and this has led to an increase in healthcare spending. Additionally, the government has made efforts to improve healthcare infrastructure and increase the availability of medication in the country. The Anti-Coagulants market in Ghana is expected to continue to grow as the population ages and healthcare services become more accessible.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.